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Several new therapeutic options emerged recently to treat metastatic melanoma; 
however, the high frequency of intrinsic and acquired resistance among patients shows 
a need for new therapeutic options. Previously, we identified the plasma membrane 
Ca2+ ATPase 4b (PMCA4b) as a metastasis suppressor in BRAF-mutant melanomas 
and found that mutant BRAF inhibition increased the expression of the pump, which 
then inhibited the migratory and metastatic capability of the cells. Earlier it was also 
demonstrated that histone deacetylase inhibitors (HDACis) upregulated PMCA4b 
expression in gastric, colon, and breast cancer cells. In this study, we treated one BRAF 
wild-type and two BRAF-mutant melanoma cell lines with the HDACis, SAHA and val-
proic acid, either alone, or in combination with the BRAF inhibitor, vemurafenib. We 
found that HDACi treatment strongly increased the expression of PMCA4b in all cell lines 
irrespective of their BRAF mutational status, and this effect was independent of ERK 
activity. Furthermore, HDAC inhibition also enhanced the abundance of the housekeep-
ing isoform PMCA1. Combination of HDACis with vemurafenib, however, did not have 
any additive effects on either PMCA isoform. We demonstrated that the HDACi-induced 
increase in PMCA abundance was coupled to an enhanced [Ca2+]i clearance rate and 
also strongly inhibited both the random and directional movements of A375 cells. The 
primary role of PMCA4b in these characteristic changes was demonstrated by treatment 
with the PMCA4-specific inhibitor, caloxin 1c2, which was able to restore the slower 
Ca2+ clearance rate and higher motility of the cells. While HDAC treatment inhibited 
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cell motility, it decreased only modestly the ratio of proliferative cells and cell viability. 
Our results show that in melanoma cells the expression of both PMCA4b and PMCA1 
is under epigenetic control and the elevation of PMCA4b expression either by HDACi 
treatment or by the decreased activation of the BRAF-MEK-ERK pathway can inhibit the 
migratory capacity of the highly motile A375 cells.
Keywords: PMca4, PMca1, hDac inhibitors, cell motility, BraF-mutant melanoma
inTrODUcTiOn
Metastatic melanoma is a highly invasive tumor type of the skin 
with poor prognosis. Although several new therapeutic options 
have emerged, the five-year survival of melanoma patients is 
only around 15% and the number of cases steadily increases in 
Western countries (1). Approximately 50% of melanomas carry a 
BRAF and 15% an NRAS mutation causing the activation of the 
mitogen-activated protein kinase (MAPK) pathway (2). In more 
than 90% of the BRAF-mutant melanoma cases, the activating 
mutation is V600E in the BRAF kinase. Specific inhibitors against 
V600E-mutant BRAF with low cross-reactivity toward wild-type 
BRAF and CRAF (3), vemurafenib and dabrafeniba initiated quick 
responses in a high percentage of patients; however, resistance 
emerged within 6–8 months in most of the cases (4). Inhibitors 
against MEK kinases were also developed, and the combination 
treatment of dabrafenib and the MEK inhibitor trametinib has 
been approved as a first-line therapy for patients with metastatic 
melanoma bearing BRAF V600E/K mutations (1). More recently, 
very promising results have been achieved with immune check-
point inhibitors (5). In monotherapy, both CTLA-4 (ipilimumab) 
and PD-1 (nivolumab and pembrolizumab) inhibitors generated 
around 30–40% response rate, while in combination this was fur-
ther increased to 60% (6). These response rates were independent 
of the BRAF mutational status of the tumor. Despite all of these 
advances, there remains a large group of patients who do not 
respond to either of these therapies or develop resistance quickly, 
requiring an ongoing search for new treatment options.
It has been known for a long time that histone acetylation is 
modified in cancer cells (7). Histone acetylation is controlled by 
the concerted action of histone acetyl transferases and histone 
deacetylases (HDACs) ultimately regulating the level of gene 
expression. HDAC inhibitors (HDACis) increase histone acetyla-
tion, leading to the activation of genes previously repressed or 
silenced in the tumor. They also have non-histone target proteins 
through which they influence other processes, such as apoptosis 
or angiogenesis (8). Three HDACis are already approved drugs 
in cancer therapy, suberoylanilide hydroxamic acid (SAHA, vori-
nostat) for cutaneous T-cell lymphoma and romidepsin and belin-
ostat for peripheral T-cell lymphomas. Other inhibitors are tested 
in different tumor types such as breast (9), colon (10), pancreatic 
(11), and lung cancer (12). In melanomas, HDACis were mostly 
used in combination treatments in both in vitro experiments and 
clinical studies. In one study, high expression of HDAC 1, 2, and 
3 was identified in all examined melanoma cell lines, while the 
expression of HDAC 4, 8, and 9 varied. HDAC expression seemed 
to be independent of the BRAF mutational status.
Upon combined treatment with the HDACi, SAHA, and the 
BRAF inhibitor, PLX4720, cell death was strongly induced in BRAF-
mutant melanoma cells, while in melanocytes the treatment caused 
very low toxicity (13). Furthermore, in PLX4720-resistant cells, 
combination treatment with SAHA was able to overcome resist-
ance and initiate cell death (13). It was also shown in melanomas 
that HDACis can decrease the expression of several anti-apoptotic 
proteins such as Bcl-XL or Bcl2, while they increase the expression 
of certain pro-apoptotic ones like BIM or BAX (14). However, there 
are substantial differences in the target spectrum of HDACis with 
distinct chemical structures. While SAHA belongs to the group 
of hydroxamic acids, another frequently used inhibitor, valproic 
acid, is a short-chain fatty acid. It was found that both SAHA and 
valproic acid were able to induce apoptosis in different melanoma 
cell lines, but they modulated apoptotic regulators differently (15).
Besides apoptosis induction, HDACis also increased immu-
nogenicity of melanoma cells. Class I HDACi treatment increased 
PD-L1 and PD-L2 expression of melanoma cells (16), while 
pan-HDACis induced upregulation of antigen-presenting MHC 
molecules (17). Several phase I and II trials have been conducted 
with HDACis in combination with other agents; however, serious 
side effects and low response rates led to the discontinuation of 
most of these attempts (18). These uncertainties about HDACi 
action further increase the need to understand the molecular 
mechanisms behind HDACi treatments.
Plasma membrane Ca2+ ATPases (ATP2B; PMCA) are Ca2+ 
pumps, which are responsible for maintaining the low cytosolic 
Ca2+ concentration. Four genes (ATP2B1-4) encode for the PMCAs 
and alternative splicing of the primary transcript generates more 
than 20 isoforms (19). PMCA1 has a housekeeping role and it is 
found in every cell type. PMCA2 and 3 isoforms are found mostly 
in excitable cells, and a particular PMCA2 isoform (PMCA2wb) 
is found in the lactating mammary gland and at distinct regions 
of the brain. PMCA4b is also ubiquitous, and its expression was 
shown to be downregulated in colon and breast cancer cells (20). It 
was also demonstrated that after treatment with short-chain fatty 
acids or trichostatin A in colon cells, and SAHA and valproate in 
breast cancer cells, its expression was strongly upregulated (9, 10).
Recently, our group identified PMCA4b as a putative metastasis 
suppressor in melanoma (21). We reported that in BRAF-mutant 
melanoma cells, PMCA4b expression is specifically upregulated 
by the inhibition of the Ras–Raf–ERK pathway with BRAF or 
MEK inhibitors. Increased abundance of this pump resulted in 
enhanced Ca2+ clearance, and its overexpression reduced migra-
tion and metastatic activity of these cells in vivo.
It has been shown in several other publications that Ca2+ played 
an important role in the regulation of migration and metastasis of 
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melanoma cells. The transient receptor potential cation channel 
subfamily M member 1 (TRPM1) Ca2+ channel was identified as 
a putative tumor suppressor in melanomas, and its expression 
negatively correlated with tumor aggressiveness (22). High levels 
of store-operated Ca2+ channel (ORAI calcium release-activated 
calcium modulator 1; ORAI1) and stromal interacting molecules 
1 and 2 (STIM1 and 2) were described in melanoma cell lines 
and melanoma tissues. Inhibition of store-operated Ca2+ entry 
resulted in decreased migratory and metastatic activity of the cells 
(23, 24). It was also demonstrated that Ca2+ oscillations initiated 
by STIM1 and ORAI1 regulated invadopodium formation and 
proteolysis in melanoma cells (25).
In this study, we investigated the effect of HDACi treatment 
alone and in combination with the BRAF inhibitor, vemurafenib, 
on PMCA expression and on Ca2+ clearance in both BRAF-mutant 
and BRAF wild-type melanoma cell lines. While BRAF inhibition 
affected only the expression of the PMCA4b isoform, we found 
that SAHA and valproic acid treatment increased the abundance of 
both PMCA1 and PMCA4b. Combination of the HDACis with the 
BRAF-specific inhibitor had similar effect as either treatment alone. 
We also found that valproic acid treatment inhibited the migration 
of the highly motile A375 cells, and this effect could be partially 
reversed by the PMCA4b-specific inhibitor caloxin 1c2. Our work 
further supports the idea that PMCA4b can inhibit the migration 
and metastasis of melanoma cells when it is upregulated, and this 
effect is independent of the activation of the MAPK pathway.
MaTerials anD MeThODs
cell culture
We used one BRAF/NRAS wild-type (MEWO) and two BRAF 
(V600E)-mutant (A375, A2058) melanoma cell lines. All the cell 
lines were purchased from ATCC and subjected to STR analysis at 
the Medical University of Vienna. We cultured the cells in DMEM 
supplemented with 10% FBS, 100 mg/ml streptomycin, 100 U/ml 
penicillin at 37°C, and 5% CO2 in a humidified atmosphere.
Treatments of cell lines
Valproic acid (sodium salt; Sigma-Aldrich) was dissolved in dis-
tilled water at the concentration of 200 mM and stored at −20°C. 
From SAHA (Sigma-Aldrich), a stock solution was prepared at 
the concentration of 100 mM in DMSO and stored at −20°C. The 
mutant BRAF (V600E)-specific inhibitor, vemurafenib (PLX4032, 
Selleck Chemicals, Munich, Germany) was dissolved in DMSO 
(100 mM) and kept at −80°C. For Western blots, 1–2 × 105 cells/
well were seeded in 6-well plates. For Ca2+ signal measurements 
and immunofluorescence staining, 1–2  ×  104 cells/well were 
placed in an Imaging Chamber 8 Well (Ibidi). Twenty-four hours 
after seeding, medium was changed to fresh medium with the 
appropriate drug. For SAHA treatment, medium was changed 
daily. The final DMSO concentration did not exceed 0.01% in any 
of the experiments.
Quantitative real-time reverse 
Transcription Pcr
mRNA of several Ca2+ channels was isolated with TRIzol reagent 
(Life Technologies) from vemurafenib- and valproic acid-treated 
and control cells. For reverse transcription, RevertAid Reverse 
Transcriptase (Thermo Scientific) was used and amplification was 
performed with the Maxima SYBR Green master mix (Thermo 
Scientific) on an Applied Biosystems® 7500 Real-Time PCR 
System. Primers used are described in Ref. (21).
Western Blot analysis
Total protein from the cells was precipitated by the addition of 6% 
TCA, and equal amounts of protein were loaded on 10% acryla-
mide gels. Samples were analyzed by Western blot as described 
previously (10). The following primary antibodies were applied: 
mouse monoclonal anti-PMCA4b (JA3, recognizing the region 
between residues 1,156–1,180, which is specific to hPMCA4b 
(26), dilution 1:1,000), anti-pan PMCA (5F10, dilution 1:5,000) 
(27), rabbit polyclonal anti-PMCA1 (Affinity BioReagents, PA1-
914, dilution 1:1,000), mouse monoclonal anti-SERCA2 (IID8, 
dilution 1:2,500, Sigma-Aldrich, S1439), mouse monoclonal 
anti-SERCA3 [PL/IM430, dilution 1:200 (10)], rabbit mono-
clonal anti-phospho-p44/42MAPK (ERK1/2) (cell Signaling, 
CST4370S, dilution 1:1,000), mouse monoclonal anti-ERK1/2 
(MK1) (Santa Cruz, sc135900, dilution 1:500), rabbit polyclonal 
anti-beta-tubulin (Abcam, ab6046), rabbit polyclonal acetyl-
Histone H3 (Lys 9/Lys 14) (cell Signaling, 9677). Subsequently 
HRP-conjugated anti-rabbit and anti-mouse secondary antibod-
ies (Jackson ImmunoResearch, dilution 1:10,000) were used, 
and detection was performed with Pierce ECL Western Blotting 
Substrate (Thermo Scientific) and luminography. Densitometric 
analysis was performed by ImageJ software v1.42q.
immunofluorescence
Cells were treated with 1.0 µM SAHA or 2 mM valproic acid for 
48 h. First, the cells were washed twice with PBS at 37°C; then, 
they were fixed with 4% paraformaldehyde for 15 min at room 
temperature. Immunostaining experiments were performed as 
described previously (9). As primary antibody, mouse monoclo-
nal anti-PMCA4b (JA3, dilution: 1:200) antibody was used. As 
secondary antibody, Alexa Flour 488-conjugated anti-mouse IgG 
(Invitrogen) was applied. Images were taken by a Zeiss LSM500 
confocal laser scanning microscope.
ca2+ signal Measurements
Cells were treated with 2.0 mM valproic acid for 48 h. In order 
to detect the intracellular Ca2+ level changes, the Fluo-4 green 
fluorescent Ca2+ indicator was used. Cells were kept in HBSS 
supplemented with 2  mM CaCl2, 0.9  mM MgCl2, and 20  mM 
HEPES pH7.4 during the entire experiment. First, cells were 
washed twice; then, they were incubated with 0.5 µM Fluo-4 AM 
(Molecular Probes, F14201) for 30 min at RT. After loading, cells 
were washed twice again. Ca2+ signals were induced by A23187 
ionophore (2 µM). In order to specifically inhibit PMCA4 activity, 
cells were incubated with caloxin 1c2 (20 µM) for 10 min followed 
by the initiation of Ca2+ signaling with the addition of A23187. 
Time-lapse images were taken by Zeiss LSM500 and Olympus 
IX81 laser scanning confocal microscopes with a 60× (1.4) oil 
immersion objective. Z-resolution was set to 1 µm, and the images 
were taken every 1  s. The relative fluorescence intensities were 
calculated as F/Fo (where Fo was the average initial fluorescence), 
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and the data were analyzed using the Prism4 software v4.01 
(GraphPad Software).
non-Directional cell Motility assay
A375 cells were seeded at 1,000 cells per well in 96-well plates 
(Greiner). The next day, the cell nuclei were stained with 0.1 µM 
Hoechst 33342 for 1 h. The cells were imaged automatically with 
ImageXpress Micro XL (Molecular Devices, Sunnyvale, CA, 
USA) high content screening system using a Nikon CFI Super 
Plan Fluor ELWD ADM 10× objective. The cells were kept at 37°C 
in a humidified atmosphere containing 5% CO2 throughout the 
measurements. The fluorescence signals for Hoechst (447/60 nm) 
were acquired at 377/50  nm excitations. Four images per field 
with 2 × 2 binning were taken every 30 min for 24 h. Motility 
analysis was performed using the Multidimensional Motion 
Analysis module of MetaXpress High Content Image Acquisition 
and Analysis Software Version 5.3. The cell nuclei were analyzed 
in a size range of 9–15 µm. The maximum distance between two 
points on the trajectory of individual cells was set to 100 µm.
Directional cell Migration assay
A modified Boyden chamber assay was previously described by 
Albini et al. (28). The assay was performed in a 48-well Boyden 
chamber (Neuro probe, Gaithersburg, MD, USA) on 10  μm-
thick uncoated Nucleopore membranes (Whatman) with pore 
diameters of 8 µm. Fibronectin (100 µg/ml Millipore) was used 
as chemoattractant in the bottom chamber. Valproate pretreated 
(4  mM, 48  h) and untreated A375 melanoma cells were placed 
into the upper chamber at 2 × 104 cells/well in DMEM containing 
10% FCS. The 20 µM caloxin 1c2 was added as appropriate, and 
cells were allowed to migrate 6 h at 37°C. The filter was removed 
from the chamber, and the cells on the upper side of the filter 
were scraped off. The migrated cells on the lower side of the filter 
were fixed with methanol and stained with toluidine blue. Cell 
migration activity was quantified as the number of migrated cells 
on the lower side of the filter using a light microscope at ×200 
magnification.
Viability assay
Viability was measured by the NucleoCounter NC-3000™ system 
(Chemometec). Cells were treated with 0.5 µM vemurafenib, 2 or 
4 mM valproate, 1 µM SAHA alone, or in combination for 48 h 
in 6-well plates. After trypsinization, two dyes were added to the 
cells: acridine orange which stained all the cells in the solution and 
DAPI which was able to stain only the non-viable cells (Solution 
13, Chemometec, 910-3013). 10 µl of each sample was loaded in an 
8-well NC slide, and the counting of cells for the two cell popula-
tions was performed. Viability was calculated from the cell counts; 
viability = total cells − non-viable cells/total cells.
cell cycle analysis
The number of cells in each cell cycle phase was determined based 
on their DNA content. Cells were treated with 0.5 µM vemurafenib, 
2 or 4 mM valproate, 1 µM SAHA alone, or in combination for 
48 h in 6-well plates. After trypsinization, cells were treated with 
lysis buffer and stained with DAPI for 5 min at 37°C. Then, the 
stabilization buffer was added and 10 µl of each sample was loaded 
onto an 8-well NC slide. Cellular fluorescence was quantified by 
the NucleoCounter NC-3000™ system (Chemometec).
resUlTs
hDaci Treatment Upregulates the 
expression of PMca1 and PMca4b in 
human Melanoma cells independent  
of the BraF Mutational status
It was previously found that inhibition of HDAC activity increased 
PMCA4b expression in breast and colon cancer cell lines (9, 10). 
More recently, we demonstrated that in BRAF-mutant melanoma 
cells BRAF inhibitor treatment had a similar effect (21). To inves-
tigate how HDACis affected PMCA expression in melanoma cells, 
we treated one BRAF wild-type (MEWO) and two BRAF-mutant 
(A375, A2058) cell lines either with increasing concentrations 
of SAHA or valproate (Figure 1A) or for different time intervals 
(Figure 1B). We found that both HDACis strongly increased the 
expression of PMCA4b in MEWO and A375 cells and to a lesser 
extent in A2058 cells. Interestingly, in response to HDACi treat-
ment, the pan-PMCA antibody, 5F10, also recognized a band just 
above the one corresponding to PMCA4b. The upper band could 
be identified as PMCA1 by using the PMCA1 isoform-specific 
antibody NR1 (Figure 2A). Both SAHA and valproate upregulated 
PMCA expression already at the lowest doses tested, 0.5 µM and 
1 mM, respectively; half-maximal response was reached at about 
1 µM concentration for SAHA and 2 mM for valproate. According 
to the time curve in Figure 1B, PMCA4b reached maximum abun-
dance after 48 h. At the longer time points, a moderate increase 
in PMCA4b expression was seen also in the control samples, in 
good accordance with previous findings, indicating that PMCA4b 
expression increases with cell confluency (29).
combination Treatment of hDacis with 
Mutant BraF inhibitor Vemurafenib  
is not additive
Combination of HDACis with targeted therapies for the treatment 
of melanoma is a possibility to overcome resistance (13). Since 
both HDAC and BRAF inhibition were able to increase PMCA4b 
expression in BRAF-mutant melanoma cells, we tested their 
combined effects. We treated two BRAF-mutant and one BRAF 
wild-type melanoma cell lines with the mutant BRAF inhibitor 
vemurafenib (0.5 µM) and with the HDACis SAHA (1 µM) and 
valproate (2 mM) alone, or in combination for 48 h (Figure 2). We 
found that in the BRAF-mutant A375 cell line vemurafenib had 
a stronger effect on PMCA4b abundance than the HDACis, and 
this was not further increased by combination with valproate or 
SAHA, while in A2058 cells HDACi treatment and BRAF inhibi-
tion had a similar effect and combination treatment with valproate 
had a slightly stronger effect than either drug alone (Figure 2B). 
In the BRAF wild-type MEWO cells, vemurafenib had no effect 
and combination treatments were similar to that of the HDACis 
alone, as expected. In good accordance with our previous results, 
PMCA1 abundance was not influenced by the BRAF inhibitor, 
vemurafenib, treatment; however, it was increased substantially 
FigUre 1 | PMca4b is upregulated in both BraF wild-type and BraF-mutant melanoma cells after histone deacetylase inhibitor (hDaci) treatment. 
(a) One BRAF wild-type (MEWO) and two BRAF-mutant (A375, A2058) cell lines were treated with HDACi SAHA or valproate in increasing concentrations for 48 h. 
DMSO (D) treatment was included as vehicle control. The protein level of PMCA4b and PMCA1 proteins were analyzed by Western blotting of total cell lysates 
(30 µg per sample) with PMCA4b-specific and pan-PMCA antibodies. Western blots were analyzed by densitometry. (B) Change in PMCA protein expression level 
was investigated after treatment with SAHA (2 µM) or valproate (2 mM) for 10, 24, 48, and 72 h with PMCA4b-specific and pan-PMCA antibodies. Western blots 
were analyzed by densitometry. Data were normalized to the expression levels of β-tubulin, and changes in PMCA4b protein level were expressed as fold increase 
over the untreated controls. Bars represent mean ± SE from three independent experiments. Asterisks indicate significant differences (*p < 0.05) from control, as 
calculated by ANOVA and Dunnett’s post hoc tests.
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by HDAC inhibition. Importantly, the staining with the antibody 
pair pERK/ERK clearly illustrates that HDACi treatment did not 
reduce ERK activation in any of the cell lines, while vemurafenib 
strongly decreased ERK phosphorylation in the BRAF-mutant 
cells (Figure  2C). In the BRAF wild-type MEWO cells, pERK 
level was slightly increased by the BRAF inhibitor treatment, 
which is in accordance with previous findings (30). This suggests 
that HDACi treatment increases PMCA abundance in an ERK-
independent manner. To verify that HDACi treatment increased 
histone protein acetylation, we compared the acetylation level of 
histone 3 protein among control and HDACi-treated cells (Figure 
S3 in Supplementary Material). We found that both SAHA and 
valproate treatment increased H3 acetylation levels in all the cell 
lines in line with previous findings (31). In contrast, vemurafenib 
treatment did not enhance H3 acetylation in these cells.
We also tested the effect of HDAC inhibition alone or in com-
bination with vemurafenib on PMCA4b expression at the mRNA 
level (Figure S1 in Supplementary Material). Cells were treated 
with valproate (2 mM) alone or in combination with vemurafenib 
(0.5  µM) for 48  h. In MEWO cells, PMCA4b expression was 
enhanced already after 8 h and further increased up to 48 h but 
then started to decline. In the A375 cells, the mRNA level of 
PMCA4b strongly increased after 24 h treatment and also started 
to decline after 48 h. In A2058 cells also PMCA4b mRNA level 
increased after 24 h but this increase was less substantial, except 
in the combination treatment, which induced strong increase.
hDacis alone or in combination  
with the BraF inhibitor Vemurafenib  
Only Moderately affected the  
expression of Other components  
of the ca2+ signaling Toolkit
The sarco/endoplasmic reticulum Ca2+ ATPases (SERCAs) are 
also important regulators of intracellular Ca2+ homeostasis, 
and the SERCA3 isoform was shown to be modified in cancer. 
FigUre 2 | combination treatment with the mutant BraF inhibitor vemurafenib and histone deacetylase inhibitors (hDaci). BRAF wild-type MEWO 
and BRAF-mutant A375 and A2058 cells were treated with the mutant BRAF inhibitor vemurafenib (0.5 µM), HDACi SAHA (1 µM), and valproate (2 mM) alone or in 
combination for 48 h. After Western blotting expression of PMCA4b, PMCA1, SERCA2, SERCA3, pERK, and ERK proteins were analyzed. As a positive control of 
PMCA1 and PMCA4b, total cell lysate of COS-7 cells was used, which endogenously express both proteins (9). (a) The expression of PMCA proteins was detected 
with isoform-specific and pan-PMCA antibodies. (B) After densitometric analysis, changes in PMCA4b (B), ERK (c) and SERCA2 (D) protein levels were normalized  
to the expression levels of β-tubulin and expressed as fold increase over the untreated controls. Bars represent mean ± SE from three independent experiments. 
Significance compared to control is denoted by asterisks (*p < 0.05), using two-tailed paired t-test.
6
Hegedüs et al. HDACi treatment increases PMCA4b Expression
Frontiers in Oncology | www.frontiersin.org May 2017 | Volume 7 | Article 95
FigUre 3 | histone deacetylase inhibitor treatment increases 
PMca4b abundance in the plasma membrane. (a) BRAF-mutant A375 
and (B) BRAF wild-type MEWO cells were treated with 1 µM SAHA, or 2 mM 
valproate for 48 h; then, the intracellular localization of PMCA4b was 
analyzed by immunofluorescence staining with anti-PMCA4b antibody (JA3). 
Images were taken by confocal microscope with a 60× objective.
7
Hegedüs et al. HDACi treatment increases PMCA4b Expression
Frontiers in Oncology | www.frontiersin.org May 2017 | Volume 7 | Article 95
Therefore, we analyzed the protein levels of SERCA2 and 
SERCA3, as well (Figure  2). We found that before treatment 
only SERCA2 was present in the melanoma cell lines and its 
protein level moderately decreased in response to HDACis in the 
BRAF-mutant cells (Figure 2D). SERCA3 expression, which is a 
known differentiation marker (32, 33), was induced by HDACi 
treatment in A2058 cells but was not detected in the other two 
cell lines.
To assess the effect of HDAC inhibition on Ca2+ channels—the 
“on” mechanisms of the Ca2+ signaling toolkit—we analyzed their 
mRNA expression before and after valproate treatment alone, or 
in combination with vemurafenib (Figure S2 in Supplementary 
Material). We found that in MEWO and A375 cells none of the 
treatments affected the expression of the inositol 1,4,5-trisphos-
phate receptor type 1–3 (IP3R1, IP3R2, IP3R3), the ORAI1, the 
stromal interaction molecule 1 and 2 (STIM1, STIM2), and the 
TRPM1. In A2058 cells, the mRNA level of IP3R3 was substan-
tially increased by valproate, whereas TRPM1 expression was 
induced only by the combination treatment. Previously, we found 
that vemurafenib induced TRPM1 expression in this cell line sug-
gesting that the increase was caused by the BRAF inhibitor in the 
combination treatment.
hDaci Treatment increased Plasma 
Membrane abundance of PMca4b  
in both Wild-Type and BraF-Mutant 
Melanoma cells
We treated one BRAF wild-type (MEWO) and one BRAF-mutant 
(A375) cell line with the HDACis, SAHA (1 µM), or valproate 
(2 mM), for 48 h and then used confocal microscopy to analyze 
the intracellular localization of PMCA4b (Figure 3). We found 
that HDAC inhibition strongly increased the abundance of 
PMCA4b in the plasma membrane of both cell lines.
enhanced ca2+ clearance initiated by  
both BraF and hDaci Treatment can Be 
Partially reverted by cotreatment with 
PMca4b-specific inhibitor, caloxin  
1c2, in a375 cells
We found previously that the vemurafenib-induced increase in 
PMCA4b abundance resulted in a faster Ca2+ clearance from 
the cells after stimulation. In order to assess whether HDACis 
had a similar effect, we measured intracellular Ca2+ signaling 
in A375 cells after valproate treatment with confocal imaging 
(Figure 4A). The Ca2+ signal was evoked by the Ca2+ ionophore 
A23187 that initiates Ca2+ uptake independently of the Ca2+ entry 
machinery. The Ca2+-sensitive fluorescent Fluo-4 indicator was 
used to monitor the changes in intracellular Ca2+ concentrations. 
For each measurement, we acquired the data with identical 
acquisition parameters and settings. We found that the Fluo-4 
fluorescence signal declined to the basal level much faster after 
the peek in the valproate treated cells than in the control cells. 
Furthermore, this effect could be reverted to a significant extent 
by the addition of the PMCA4-specific inhibitor, caloxin 1c2, 
which inhibited the decay phase of the Ca2+ signal (Figures 4B,C). 
These results show that PMCA4b is primarily responsible for the 
increased Ca2+ clearance after HDACi treatment in these cells.
The effect of hDaci Treatment alone and 
in combination with BraF inhibition on 
cell Viability and cell cycle Progression
Histone deacetylase inhibition was previously shown to induce 
apoptosis and to decrease proliferation in a variety of cancer cells. 
Furthermore, the combination of BRAF and HDACis increased 
cell death and even overcame resistance in BRAF-mutant mela-
noma cells (13). We treated the three melanoma cell lines (MEWO, 
A2058, and A375) with HDAC and BRAF inhibitors alone and in 
combination for 48  h and tested their viability (Figure  5). We 
found that none of the treatments affected significantly the viabil-
ity of the BRAF wild-type MEWO cells, and BRAF-mutant A2058 
cells (Figures 5A1,C1). In the A375 cells, vemurafenib alone or in 
combination with SAHA decreased the cell viability slightly, but 
significantly (Figure 5B1).
We also analyzed the distribution of the cells among the cell 
cycle phases after the various treatments (Figure  5). In these 
measurements, we distinguished four cell cycle phases; the rest-
ing G0/G1 phase, the synthesis S phase, the G2/M phase with 
cells having two sets of paired chromosomes, and the sub-G1 
phase with dying cells. We found that the effect of the treatments 
was cell line dependent. In A375 cells, as expected, prolifera-
tion strongly decreased in the presence of vemurafenib (G2/M 
phase cells) (Figure  5C3), while HDACis alone had no effect. 
Vemurafenib induced cell death (sub-G1) in approximately 10% 
of the cells (Figure  5B3). This effect was further increased by 
combination with valproate but not with SAHA. HDACis alone 
only slightly increased cell death compared to control in this cell 
FigUre 4 | histone deacetylase inhibitor treatment increases ca2+ clearance in BraF-mutant a375 cells through PMca4b activity. (a) Ca2+ signaling 
measurement was performed after 48 h of treatment with 2 mM valproate. External media were changed to HBSS supplemented with 2 mM Ca2+, and cells were 
filled with intracellular Ca2+ indicator, Fluo-4. The Ca2+ signal was initiated by 2 µM A23187. (B) The PMCA4-specific inhibitor, caloxin 1c2 (20 mM) was added 
10 min before stimulation with A23187 to the valproate-treated cells. Data represent fluorescent intensity values of 10–15 cells. (c) Half-peak decay time of the 
A23187-induced Ca2+ signal was determined after treatment with valproate alone or in combination with the PMCA4 inhibitor, caloxin 1c2, compared to control. Bar 
graphs are mean ± SD of individual cells taken from two to three independent experiments. Significance between control and valproate- or vemurafenib-treated cells 
is denoted by ***p < 0.001; two-tailed unpaired t-test.
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line. In A2058 cells, SAHA decreased significantly the number of 
cells in the G2/M phase, valproate alone did so to a lesser extent 
(Figure  5C3), but in combination with vemurafenib the effect 
was stronger. Treatment with SAHA alone and also in combina-
tion with vemurafenib increased the ratio of dying cells in this 
cell model (Figure 5C2). MEWO cells responded exclusively to 
SAHA treatment with decreased proliferation and none of the 
treatments induced cell death in these cells (Figures  5A2,A3). 
Based on these data, we conclude that HDACis alone decreased 
only modestly the viability and proliferation of melanoma cells, 
while combination treatments had a more substantial effect, 
although in a cell-type specific manner.
hDaci Treatment strongly Decreases  
the Migratory activity of a375 Melanoma 
cells in a PMca4b-Dependent Manner
We found previously that increased expression of PMCA4b in 
A375 cells resulted in decreased migratory activity. We assessed 
the effect of HDAC inhibition on both the random and direc-
tional migration of A375 cells (Figure 6). In all the experiments, 
the cells were treated with valproate (4 mM) for 48 h before the 
migration analysis. Random migration was recorded by using 
automated fluorescence microscopy (ImageXpress Micro XL) 
for 24 h. Representative trajectories of single cells after 48 h of 
valproate treatment clearly show that valproate strongly inhib-
ited the migration of A375 cells (Figure  6A1). The velocity of 
valproate-treated cells decreased significantly compared to the 
untreated control cells (Figure 6A2). This effect was similar to 
that described previously for vemurafenib-treated A375 cells (21).
Directed migration of A375 cells was assessed using modified 
Boyden chamber assay (Figure  6B), in which fibronectin was 
used as a chemoattractant. Cells were allowed to migrate through 
the pores of the Boyden Chamber membrane for 6 h toward the 
fibronectin coat. We observed a sharp decrease in the directional 
movement of A375 cells pretreated with valproate, compared to 
that of the untreated cells (Figure 6B1). A half-maximal response 
of cells could be achieved at approximately 2  mM valproate 
treatment (Figure  6B2), which was comparable to that of the 
PMCA4b protein expression response to valproate under similar 
conditions (Figure  1A, middle panels). To evaluate the role of 
PMCA in this effect, we added the PMCA4-specific inhibitor, 
caloxin 1c2, to the cells immediately before the assay. Inhibition 
of PMCA4 resulted in a modest but significant increase in the 
directional migration activity in both the control and valproate-
treated cells (Figure  6C) suggesting that PMCA4 activity is 
involved in the control of A375 cell motility.
DiscUssiOn
Histone deacetylases are upregulated in many types of cancers 
(34) resulting in aberrant histone deacetylation that supposedly 
is associated with transcriptional repression of a variety of tumor 
suppressor genes. Previously, we identified PMCA4b as a putative 
metastasis suppressor in melanoma A375 cells that has the ability 
to suppress cell migration and metastasis without affecting cell 
proliferation (21). We also demonstrated that the expression of 
PMCA4b is enhanced in response to BRAF inhibition. In the cur-
rent study, we show that the expression of this protein is under 
epigenetic control in melanoma cells.
Previously, it was demonstrated that in gastric and colon 
cancer cells short-chain fatty acid and trichostatin A treatment 
strongly increased the expression of PMCA4b and only moder-
ately that of PMCA1b. Similar results were obtained after sponta-
neous differentiation of post-confluent cultures of these cells (10, 
35). Furthermore, it has been shown that protein expression of 
PMCA4b is reduced in high-grade adenoma, colon cancer, and 
lymph node metastasis compared to normal mucosa, while the 
expression of PMCA1 remained unchanged (20). Similarly, in 
the breast cancer cell line, MCF-7 HDACi treatment markedly 
induced the expression of PMCA4b but not that of PMCA1b (9). 
In this work, we show that HDACi treatment induces significantly 
the abundance of PMCA4b in melanoma cells, irrespective of their 
BRAF mutational status but in a cell-type-dependent manner. 
FigUre 5 | analysis of viability and cell cycle after treatment with histone deacetylase inhibitors alone and in combination with the BraF inhibitor, 
vemurafenib. Cells were treated with SAHA (1 µM), valproate (2 or 4 mM), and vemurafenib (0.5 µM) alone or in combination for 48 h. (a) The percentage of viable cells 
was determined by counting the number of total and non-viable cells. (B) The ratio of cells in sub-G1 and G2/M cell cycle phases was determined based on the cell’s 
DNA content. Data are means of three independent determinations. Significance compared to control is denoted by asterisks (*p < 0.05); two-tailed paired t-test.
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Furthermore, a substantial increase in the abundance of the 
housekeeping isoform, PMCA1was also seen in the two BRAF-
mutant cell lines, A375 and A2058, but not in BRAF wild-type 
MEWO cells. We demonstrated that in A375 cells the enhanced 
PMCA4b level increased Ca2+ removal from the cytosol, which 
coincided with a decreased migratory potential of these highly 
motile cells. Selective inhibition of PMCA4b activity partially 
reversed the effect of HDAC inhibition on both the Ca2+ signal 
and the directional movement of A375 cells, providing additional 
evidence that PMCA4b has a primary role in the regulation of cell 
motility in this cell line.
Another important finding of the current study is that combi-
nation of the two drugs, HDACi and vemurafenib, did not result in 
any substantial additional effect on the PMCA expression. These 
data suggest that in these melanoma cell lines the expression of 
both PMCA1 and PMCA4b is downregulated by epigenetic fac-
tors. One possible explanation for the lack of additivity between 
BRAF and HDAC inhibition on PMCA4b expression is that the 
effect of ERK inhibition could itself be indirect and be mediated 
by histone acetylation (36). Although vemurafenib treatment 
did not affect H3 histone acetylation in the melanoma cell lines 
used in our studies, it is still conceivable that acetylation of other 
FigUre 6 | histone deacetylase inhibitor treatment strongly decreases the migratory activity of a375 melanoma cells in a PMca4b-dependent 
manner. A375 cells were treated with 4 mM valproate for 48 h before the migration analysis. (a) The random migratory activity of A375 melanoma cells was 
analyzed by automated fluorescence microscopy for 24 h (A1). Single cell migration trajectories of untreated, control cells (left graph) and valproate-treated cells 
(right graph) were recorded. Starting position of each cell trajectory was fixed to the origin of the plot. (A2) Mean velocity was evaluated for 24 h of migration. Data 
are shown as mean ± SEM of ≥100 individual cells of at least three independent measurements. Significance compared to control is denoted by ***p < 0.001; 
two-tailed unpaired t-test. (B,c). Effect of valproate treatment of A375 cells (B) and specific inhibition of PMCA4 with caloxin 1c2 (c) on the directional migration of 
A375 cells. The effect of PMCA4 inhibition was studied on untreated (C1) and 4 mM valproate-treated (C2) A375 cells. The directional migration activity was 
assessed using Boyden chambers. B1 images show representative fields of view from the bottom of the filter (control and 4 mM valproate-treated A375 cells).  
B2 shows migration of cells in response to different concentrations (1–5 mM) of valproate. The cells that migrated through the membrane to the bottom face were 
counted. The bar graphs (B2, C1, C2) indicate the average number of migrated cells per field. Data are mean of three experiments ± SEM. Significance of 
comparisons is denoted by ***p < 0.001; two-tailed unpaired t-test.
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histones is responsible for the regulation of PMCA4b expression 
by vemurafenib.
It is possible that decreased expression of PMCAs might con-
tribute to the maintenance of an elevated intracellular calcium 
level. In contrary, increased expression of several types of Ca2+ 
channels was identified in both melanoma cells and melanoma 
tissues, and the inhibition of these channels led to increased 
cell death and decreased metastatic activity. Transient receptor 
potential cation channels (TRPM1, 2,7 and 8) have been shown 
to be upregulated in melanomas (22), where they contributed 
to increased proliferation and metastatic capacity. In addition, 
elevated expression of the store-operated Ca2+ channels, ORAI1 
and ORAI2, and of the stromal interacting molecule 1 and 2 
(SOCE) was also described. Inhibition of SOCE decreased both 
melanoma cell proliferation and migration (23, 24).
Previously, we demonstrated that PMCA activity can reduce 
the SOCE-mediated Ca2+ signal (37) and most recently that 
PMCA4b can inhibit melanoma cell migration. A direct role of 
PMCA4b in the regulation of migration was also demonstrated 
in VEGF-treated endothelial cells (38), which involved the NFAT 
pathway. During collective migration of human umbilical vein 
endothelial cells (39), PMCA4b showed polarized localization, 
necessary to maintain the intracellular Ca2+ gradient characteris-
tic of directionally migrating cells.
In the current study, we demonstrated that in melanoma cells 
PMCA4b expression is regulated through histone acetylation. 
Upregulation of PMCA4b abundance through the inhibition of 
HDACs resulted in a significant decrease in cell motility of the 
highly invasive A375 cells. HDACis had a similar effect to what 
was shown previously with vemurafenib treatment. While HDAC 
inhibition affects the expression of a broad range of proteins, the 
specific role of PMCA4b in the regulation of cell migration of 
A375 cells was confirmed by the reverting effect of the PMCA4b-
specific inhibitor, caloxin 1c2. It is also important to note that the 
expression of the SOCE channels (STIM or ORAI) was not affected 
by the treatments, indicating that SOCE could not be responsible 
for the suppressed migratory capacity of the HDACi-treated cells.
At the transcriptional level, PMCA1 is under tight control. 
Vitamin D is one of its known regulators which has been shown to 
induce PMCA1 expression effectively in the small intestine, kid-
ney distal tubules, and osteoblasts (40). More recently, PMCA1 
upregulation was observed in colon cancer cells (41). Targeted 
deletion of PMCA1 in mice resulted in impaired responsiveness 
to 1,25-dihydroxyvitamin D3, the active metabolite of vitamin D, 
and in decreased bone mineral density (42). Recent clinical stud-
ies have suggested that melanoma patients with lower levels of 
vitamin D may have poorer survival (43, 44). As vitamin D exerts 
its gene regulatory effect by attracting HDACis to the promoter 
region of target genes, our results suggest that vitamin D might 
regulate PMCA1 expression by epigenetic mechanisms.
The SERCAs play an important role in the regulation of the 
intracellular Ca2+ homeostasis. There is not much known, how-
ever, about their role in cell migration. SERCA2 has been shown 
to decrease the migratory capacity of dendritic cells in response to 
the chemokine CCL21 (45), while it was demonstrated that nitric 
oxide-mediated activation of SERCA2b is necessary for VEGF-
induced endothelial cell migration (46). We found that in A375 
cells only SERCA2, the housekeeping isoform, was present and 
its expression was decreased by treatment with SAHA but was 
not effected by valproate. Since in both of our migration model 
systems we used valproate treatment, it is unlikely that SERCA2 
affected the migratory capacity of these cells.
As it has been shown previously that HDAC inhibition 
induced apoptosis in various cancer types, we investigated the 
effect of SAHA, valproate, and vemurafenib on the viability and 
cell cycle progression of these three melanoma cell lines. We 
found that viability was not affected substantially in any of the 
cell lines tested, while the ratio of proliferating cells was altered in 
a cell-type-dependent manner. A375 cells, which are highly sensi-
tive to the BRAF inhibitor, vemurafenib, reacted more efficiently 
to vemurafenib treatment than to either of the HDACis alone. 
Combination of the two types of drugs could further increase the 
number of cells in the sub-G1 phase. In A2058 cells, which carry 
also a mutation in the tumor suppressor PTEN, vemurafenib had 
only a small effect on the number of cells in the G2/M phase; 
however, SAHA and valproate in combination with vemurafenib 
could decrease their ratio significantly. The moderate effect on 
cell death in our treatments is in good accordance with the results 
of others (47), who found strong increase in cell death only at 
much higher concentration of HDACis (13).
Overall, our data show that the HDACis, SAHA and valproate, 
enhanced the expression of the previously recognized metastasis 
suppressor PMCA4b in an ERK-independent manner and 
reduced the cell motility without having substantial influence 
on cell proliferation. Specific inhibition of PMCA4b activity 
partially blocked the effect of HDACis underlining the role of 
PMCA4b in the regulation of cytosolic Ca2+ concentration and 
cell motility. Moreover, the HDACis also enhanced the expression 
of the housekeeping PMCA1 isoform in the BRAF-mutant cells, 
suggesting an even more complex role of the PMCAs in the Ca2+ 
homeostasis of melanoma cells. Our results support the further 
evaluation of HDACis alone or in combination with other drugs 
for the treatment of metastatic melanoma.
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